These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24403296)

  • 1. Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial.
    Horne BD; Anderson JL; Muhlestein JB; Ridker PM; Paynter NP
    Eur J Prev Cardiol; 2015 Apr; 22(4):519-26. PubMed ID: 24403296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Statin Adherence on Cardiovascular Morbidity and All-Cause Mortality in the Primary Prevention of Cardiovascular Disease: A Population-Based Cohort Study in Finland.
    Rannanheimo PK; Tiittanen P; Hartikainen J; Helin-Salmivaara A; Huupponen R; Vahtera J; Korhonen MJ
    Value Health; 2015 Sep; 18(6):896-905. PubMed ID: 26409618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary-Specific Intermountain Risk Score Predicts All-Cause Mortality via Spirometry, the Red Cell Distribution Width, and Other Laboratory Parameters.
    Horne BD; Hegewald M; Muhlestein JB; May HT; Huggins EJ; Bair TL; Anderson JL
    Respir Care; 2015 Sep; 60(9):1314-23. PubMed ID: 25873741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the dispersion in red blood cell volume with mortality.
    Horne BD; Muhlestein JB; Bennett ST; Muhlestein JB; Ronnow BS; May HT; Bair TL; Anderson JL
    Eur J Clin Invest; 2015 Jun; 45(6):541-9. PubMed ID: 25753860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red blood cell distribution width and the risk of cardiovascular morbidity and all-cause mortality. A population-based study.
    Arbel Y; Weitzman D; Raz R; Steinvil A; Zeltser D; Berliner S; Chodick G; Shalev V
    Thromb Haemost; 2014 Feb; 111(2):300-7. PubMed ID: 24173039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical laboratory-based clinical decision tools and associations with short-term bleeding and mortality outcomes.
    Graves KG; Muhlestein JB; Lappé DL; McCubrey RO; May HT; Knight S; Le VT; Bair TL; Anderson JL; Horne BD
    Clin Chim Acta; 2018 Jul; 482():166-171. PubMed ID: 29627489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red cell distribution width is predictive of mortality in trauma patients.
    Majercik S; Fox J; Knight S; Horne BD
    J Trauma Acute Care Surg; 2013 Apr; 74(4):1021-6. PubMed ID: 23511140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
    Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
    Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between red blood cell distribution width and the clinical outcomes in non-ST elevation myocardial infarction and unstable angina pectoris: a 3-year follow-up.
    Gul M; Uyarel H; Ergelen M; Karacimen D; Ugur M; Turer A; Bozbay M; Ayhan E; Akgul O; Uslu N
    Coron Artery Dis; 2012 Aug; 23(5):330-6. PubMed ID: 22735091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Askevold ET; Gullestad L; Nymo S; Kjekshus J; Yndestad A; Latini R; Cleland JG; McMurray JJ; Aukrust P; Ueland T
    PLoS One; 2015; 10(8):e0133970. PubMed ID: 26288364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.
    Ueland T; Dahl CP; Kjekshus J; Hulthe J; Böhm M; Mach F; Goudev A; Lindberg M; Wikstrand J; Aukrust P; Gullestad L
    Circ Heart Fail; 2011 Mar; 4(2):145-52. PubMed ID: 21216833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red cell distribution width and risk of cardiovascular mortality: Insights from National Health and Nutrition Examination Survey (NHANES)-III.
    Shah N; Pahuja M; Pant S; Handa A; Agarwal V; Patel N; Dusaj R
    Int J Cardiol; 2017 Apr; 232():105-110. PubMed ID: 28117138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
    Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
    Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.
    Lawler PR; Akinkuolie AO; Chandler PD; Moorthy MV; Vandenburgh MJ; Schaumberg DA; Lee IM; Glynn RJ; Ridker PM; Buring JE; Mora S
    Circ Res; 2016 Apr; 118(7):1106-15. PubMed ID: 26951635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease.
    Anderson JL; Ronnow BS; Horne BD; Carlquist JF; May HT; Bair TL; Jensen KR; Muhlestein JB;
    Am J Cardiol; 2007 Jan; 99(2):169-74. PubMed ID: 17223413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL
    Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy.
    Tada H; Nomura A; Yoshimura K; Itoh H; Komuro I; Yamagishi M; Takamura M; Kawashiri MA
    Circ J; 2020 Feb; 84(3):509-515. PubMed ID: 32023582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group IIA Secretory Phospholipase A
    Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Wells MT; Eisenberg T
    Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.